Answers are grounded in this paper and cite their sources.
Comprehensive review shows various fertility preservation options in cancer survivors, indicating enhanced reproductive health prospects.
Recent advancements in cancer therapy and reproductive technologies have given new possibilities for fertility preservation (FP) in cancer survivors. FP is the procedure to preserve sperm, egg, embryo, and reproductive tissue with the goal of preserving fertility and maintaining reproductive health in people who are at risk of adverse effects of gonadotoxic treatment, non-oncologic malignancies, age-related complications, and certain metabolic or autoimmune disease conditions. Earlier results on survival and live birth rates in embryo and oocyte/semen cryopreservation in post-pubertal patients indicate that FP methods are first-line, whereas in prepubertal patients, ovarian or testicular tissue cryopreservation and subsequent transplantation are recommended. New approaches such as orthotopic transplantation, cryopreserved tissue, or artificial ovarian maturation in vitro , or activation of folliculogenesis or spermatogenesis in vitro have also been developed. However, further research and prior preservation counselling for all patients is required for those who are at risk. The current review mainly focuses on different options of FP techniques in patients undergoing gonadotoxic cancer treatments for preserving their reproductive health and future fertility.
No takes yet. Share an insight, caveat, or question.
Kaingade et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: